Tempus Multimodal Immune Profile Score Test
Tempus AI has launched a research-use-only version of its multimodal immune profile score (IPS) algorithmic test. IPS is a pan-cancer, laboratory-developed test that assesses a combination of immunotherapy-related biomarkers from prior DNA and RNA test results to calculate a score from zero to 100 and a classification of either IPS-Low or IPS-High. IPS results can support patient stratification across pan-cancer cohorts to help inform response to immunotherapy. The IPS test is intended to be an add-on option for clinicians ordering Tempus' xT and xR at the end of the year.